Thymalin
Thymic peptide fraction
A thymic-derived peptide studied in immunomodulatory research.
Overview
Thymalin is a peptide preparation derived from a fraction of calf (bovine) thymus tissue, developed in Russia as a thymic bioregulator. It is a polypeptide/peptide complex rather than a single defined-sequence peptide.
At a glance
What Thymalin does
Thymalin is a polypeptide complex extracted from the thymus glands of young calves, composed of short peptides (roughly 2-8 amino acids) that are thought to reproduce the signaling activity of a healthy, youthful thymus. Functionally it is characterized as an immunomodulating 'peptide bioregulator': rather than broadly stimulating immunity, it is described as restoring balance to a dysregulated immune system, most notably normalizing T-cell subset ratios in people with age-related or secondary immunodeficiency. It emerged from Khavinson's 1970s work on restoring immune function in radiation- and stress-exposed subjects and was approved as a pharmaceutical in the Soviet Union in 1982, making it one of the earliest peptide drugs.
In research reports its actions center on the adaptive immune compartment. Thymalin has been described as increasing CD4+ T-cell counts, improving CD4/CD8 ratios, and enhancing lymphocyte proliferative responses to mitogens in aged or immunocompromised subjects, effectively pushing an involuted, aging thymic output back toward a younger profile. It is used clinically in Russia and Eastern Europe for immune deficiency, recovery from chemotherapy or radiation, and chronic infection.
The most cited human data are long-term observational cohorts of elderly subjects: those given annual thymalin injections reportedly showed mortality roughly 2-fold lower than untreated controls, with further benefit when combined with epithalamin. These findings are striking but come largely from a single research lineage and are not independently replicated to Western regulatory standards. Thymalin is not FDA-approved and is not legally sold for human use in the US, so its immune-restoring effects should be regarded as promising but not rigorously confirmed outside its country of origin.
Effects reported in research
- Reported to normalize T-lymphocyte subset ratios (CD4/CD8) in subjects with age-related or secondary immunodeficiency.
- Associated with increased CD4+ T-cell counts in aged and immunocompromised subjects (clinical, single research lineage).
- Enhanced lymphocyte proliferative responses to mitogens in treated subjects.
- Characterized as an immune bioregulator that restores balance to a dysregulated immune system rather than broadly over-stimulating it.
- In long-term elderly cohorts, annual injections were associated with roughly 2-fold lower mortality versus untreated controls (observational clinical data).
- Combined with epithalamin, mortality reduction was reported to be greater still (~2.5-fold) in the same cohorts.
- Used clinically in Russia/Eastern Europe to support immune recovery after chemotherapy and radiation and in chronic infection.
- Not FDA-approved and not independently replicated to Western standards; effects derive largely from Khavinson-lineage studies.
Effects listed reflect findings reported in the research literature — many in animal or in-vitro models. Listing an effect is not a claim of efficacy or a therapeutic indication in humans.
Mechanism of action
Thymalin is described as a thymic peptide preparation reported to modulate immune function, particularly influencing T-lymphocyte differentiation and the balance of immune cell populations. As a mixture of thymic peptides, its actions are attributed to restoring or regulating immune parameters in preclinical and clinical research from the Russian literature. The precise molecular targets are not fully defined given its nature as a peptide fraction.
Mechanistic description reflects published research-literature understanding. Much peptide research is preclinical (in-vitro or animal-model); mechanism in humans may differ and is not established for many compounds.
What it's studied for
Research contexts in which Thymalin appears in the literature. Listing a research area is not a claim of efficacy or a therapeutic indication.
Key characteristics
- A thymus-derived peptide preparation, not a single-sequence synthetic peptide
- Developed as a thymic bioregulator in Russian research
- Reported to influence T-lymphocyte populations and immune balance
- Defined sequence and molecular weight are not applicable (peptide fraction)
- Evidence is largely from Russian-language preclinical and clinical studies
- Distinct from the single-peptide Thymosin alpha-1
Reported research dosing reference only
Educational reference, not dosing guidance. The figures below summarize amounts reported in published research and research-community protocols, provided for educational and research context only. They are not medical advice, not a recommendation, and not instructions for human use. Thymalin is a research compound.
Reported Khavinson-lineage clinical protocols describe short cycles of intramuscular or subcutaneous injection over several days, repeated a few times per year. These are reference figures for research context only, not dosing guidance for humans.
- Standard Khavinson protocol reference: 5-10 mg/day for 5-10 consecutive days per cycle
- Cycles typically repeated 2-4 times per year in reported protocols
Because thymalin is an extract mixture rather than a single molecule, potency is standardized by process/mass rather than by a defined peptide concentration.
How it compares
Unlike Thymosin alpha-1 (a single, defined 28-residue peptide), Thymalin is a multi-peptide thymic tissue fraction, so it has no single sequence or molecular weight.
Commonly studied alongside
Compounds frequently researched together with Thymalin in the literature. Cross-referenced for research context — not a usage or combination recommendation.
Handling & Stability
Lyophilized peptides are stored cold, protected from light, and reconstituted only at the time of intended in-vitro work.
- Avoid repeated freeze-thaw cycles
- Verify supplier lot and Certificate of Analysis
- Follow institutional lab-safety protocols
Analytical & COA Concepts
Reputable research suppliers publish a third-party Certificate of Analysis per batch. Key analytical concepts referenced in COAs include:
Category Context
Thymalin sits in the Longevity & Cellular area of the PeptiDex library.
- Entry type: Research compound reference
- Browse the full library →
- Glossary of terms →
Where researchers source Thymalin
For researchers studying Thymalin, third-party suppliers such as Practically Natty Peptides offer research-grade material with third-party Certificates of Analysis and US-based shipping.
View research-supplier listing →
Outbound link to a third-party research supplier. Inclusion does not constitute endorsement; all editorial content is developed independently.
Frequently asked questions
What is thymalin?
Thymalin is a low-molecular-weight polypeptide fraction extracted from calf (bovine) thymus, developed in Russia by Khavinson and Morozov. It is a heterogeneous complex of short peptides rather than a single defined molecule, and is studied as an immunomodulator that reportedly normalizes rather than simply boosts immune parameters.
How does thymalin differ from thymosin alpha-1?
Thymosin alpha-1 is a single, chemically defined 28-amino-acid peptide with a known sequence, whereas thymalin is a defined-process but undefined-composition extract containing a mixture of thymic peptides. Batch-to-batch peptide ratios can vary in thymalin, unlike the single synthetic molecule of thymosin alpha-1.
What is thymalin studied for?
Thymalin is studied in immune-senescence and aging research for reported restoration of T-cell counts, CD4/CD8 ratios, and NK-cell activity in older populations. Khavinson-era observational studies also reported reduced mortality in elderly cohorts, though these were non-randomized and are considered preliminary.
Does thymalin have a defined sequence or molecular weight?
No single sequence or molecular weight applies, because thymalin is a mixture of thymic peptides typically spanning roughly 1-10 kDa. This is why sequence and molecular-weight fields are best left unspecified for thymalin.
How is thymalin administered in research protocols?
Reported Khavinson-style protocols use short courses of intramuscular or subcutaneous injection over several consecutive days, repeated periodically through the year. It is supplied lyophilized and reconstituted before use.
Answers are educational summaries of research-literature context and do not constitute medical advice. See the Research Library, COA guide, and Storage & Handling guide for more.